Stefan K. Barta
Experienced in Autoimmune Hemolytic Anemia

Dr. Stefan K. Barta

Hematology Oncology | Transplant Surgery | Hematology
University Of Penn - Medical Group
3400 Spruce St, 
Philadelphia, PA 
 (334.1 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
24 Years of Experience
Experienced in Autoimmune Hemolytic Anemia
University Of Penn - Medical Group
3400 Spruce St, 
Philadelphia, PA 
 (334.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

Stefan Barta is a Hematologist Oncology specialist and a Transplant Surgeon in Philadelphia, Pennsylvania. Mr. Barta has been practicing medicine for over 24 years and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 124 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Autoimmune Hemolytic Anemia.

Specialties
Hematology Oncology
Transplant Surgery
Hematology
Licenses
Internal Medicine in PA
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna

Locations

UNIVERSITY OF PENN - MEDICAL GROUP
3400 Spruce St, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Randomized Phase II Study of CHO(E)P Vs CC-486-CHO(E)P Vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A Randomized Phase II Study of CHO(E)P Vs CC-486-CHO(E)P Vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Enrollment Status: Recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine
Study Phase: Phase 2
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Recruiting
Publish Date: January 30, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Alisertib, Bortezomib, Rituximab
Study Phase: Phase 1
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Early Phase 1
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Other, Drug
Study Drug: Nelfinavir Mesylate
Study Phase: Phase 2
A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-cell Lymphoma
A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drugs: Romidepsin, Brentuximab vedotin
Study Phase: Phase 1
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: August 24, 2022
Intervention Type: Drug
Study Drugs: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Study Phase: Phase 1
A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: July 08, 2022
Intervention Type: Drug
Study Drugs: MK-3475, Copanlisib
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Drug
Study Drugs: Decitabine, Carboplatin, Arsenic Trioxide
Study Phase: Phase 2
Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
Enrollment Status: Completed
Publish Date: May 06, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia
A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: September 06, 2019
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

124 Total Publications

Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B Cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy.
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B Cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy.
Journal: Transplantation and cellular therapy
Published: October 08, 2024
Similar Doctors
Distinguished in Autoimmune Hemolytic Anemia
Dr. Lewis J. Rose
Hematology Oncology | Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Lewis J. Rose
Hematology Oncology | Hematology | Oncology

Aria Health Physician Services

10800 Knights Rd, 
Philadelphia, PA 
 (13.9 mi)
215-890-3030
Languages Spoken:
English
See accepted insurances

Lewis Rose is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Rose and is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Autoimmune Hemolytic Anemia, Vulvar Cancer, Paget Disease of the Breast, and Posterior Fossa Tumor.

Distinguished in Autoimmune Hemolytic Anemia
Dr. Subhash C. Proothi
Hematology Oncology | Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Subhash C. Proothi
Hematology Oncology | Hematology | Oncology

St Lukes Physician Group Inc

1736 W Hamilton St, 
Allentown, PA 
 (47.4 mi)
610-954-3571
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Subhash Proothi is a Hematologist Oncology specialist and a Hematologist in Allentown, Pennsylvania. Dr. Proothi and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Thrombocytopenia, Adult Immune Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Childhood Iron Deficiency Anemia.

Advanced in Autoimmune Hemolytic Anemia
Dr. Charles S. Abrams
Hematology Oncology | Oncology | Hematology
Advanced in Autoimmune Hemolytic Anemia
Dr. Charles S. Abrams
Hematology Oncology | Oncology | Hematology

University Of Penn - Medical Group

3400 Spruce St, Department Of Pathology And Lab Medicine, 
Philadelphia, PA 
215-662-6503
Languages Spoken:
English
See accepted insurances

Charles Abrams is a Hematologist Oncology specialist and an Oncologist in Philadelphia, Pennsylvania. Dr. Abrams and is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Autoimmune Hemolytic Anemia, Thrombocytopenia, Shwartzman Phenomenon, and Evans Syndrome.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile